Silver Bullet Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
The standard of care for osteomyelitis has not changed over the past half century: long-term intravenous antibiotics with multiple agents and doses administered daily and typically lasting a full 12 weeks, followed by oral medications for an additional several months to a year. Silver Bullet Therapeutics Inc. is developing a temporary, implantable silver-eluting implant to fight infection in tandem with IV antibiotics. The company's founders say it should shorten the duration of IV therapy by half.